What is Profluent Bio?
Headquartered in Berkeley, California, and founded in 2022, Profluent Bio operates at the intersection of computational biology and machine learning. The company specializes in developing sophisticated generative models capable of designing proteins that do not exist in nature, effectively bypassing the limitations of traditional discovery methods. By focusing on the functional validation of these synthetic proteins, Profluent is carving out a unique market position as an AI-first engine for therapeutic development. Its platform is designed to accelerate the timeline from protein conceptualization to clinical application, offering a scalable solution for complex biological challenges that have historically hindered pharmaceutical innovation.
How much funding has Profluent Bio raised?
Profluent Bio has raised a total of $141M across 2 funding rounds:
Other Financing Round
$35M
Other Financing Round
$106M
Other Financing Round (2024): $35M with participation from Insight Partners, Spark Capital, and Air Street Capital
Other Financing Round (2025): $106M led by Spark Capital, Altimeter Capital, Bezos Expeditions, and Insight Partners
Key Investors in Profluent Bio
Spark Capital
A multi-stage venture capital firm known for backing transformative technology companies across various sectors, providing both capital and strategic guidance to founders.
Insight Partners
A global investment firm specializing in high-growth software and technology companies, offering extensive operational support to help firms scale from early stages to public markets.
Bezos Expeditions
An investment firm founded by Jeff Bezos that focuses on high-impact sectors including healthcare, technology, and space exploration, supporting innovative companies with long-term growth potential.
What's next for Profluent Bio?
With this latest infusion of capital, Profluent Bio is well-positioned to scale its computational infrastructure and expand its internal pipeline of therapeutic candidates. The company's strategic roadmap likely involves deepening its research into protein-based therapeutics while potentially exploring partnerships with established pharmaceutical entities to validate its generative models in real-world clinical settings. As the firm transitions from its early-stage development phase into a more mature enterprise-level operation, the focus will shift toward optimizing its proprietary AI architecture to handle increasingly complex protein structures, thereby solidifying its competitive advantage in the rapidly evolving biotech sector.
See full Profluent Bio company page
